Andrea Gropman, M.D. is a neurogeneticist and international expert in Urea cycle disorders (UCD), Smith Magenis syndrome (SMS), X and Y chromosome aneuploidies, and mitochondrial disorders.' Her research has focused on 1) multimodal imaging in urea cycle disorders and other neurogenetic conditions to establish neural biomarkers of connectivity and brain injury; 2) sleep disorders and cognitive phenotype in SMS; 3) cognitive and neurological aspects of X and Y chromosome disorders; and 4)functional mitochondrial studies and therapeutics. She has presented her work at both national and international conferences in neurology, genetics, and metabolism. She serves on the neurotherapeutics committee of ACMG, community education outreach (PEAK) at ASHG, American Brain Coalition as the designated representative from the Child Neurology Society, the education committee of SIMD, the annual program committee of the American neurological society, past chair of the Neurogenetics Special interest group at ANA, and the chair of neurogenetics at Child Neurology society.' She is the principal investigator of the urea cycle rare disease consortium.' For the past 25 years she was the division chief of neurogenetics, a division she created, served as NDD fellowship director, director of clinical translational research and interim director of the genetic medicine center. In October 2024, she moved to St Jude to build a neurometabolic translational research program and a neurogenetics/neurotherapeutics fellowship program.